Search Results - "Maslow, Joel"

Vaccine development for emerging virulent infectious diseases by Maslow, Joel N

“…Highlights • Emerging Infectious Diseases require novel approaches to vaccine development. • EID vaccine development typically occurs within a knowledge…”
Get full text

GeneOne Life Science by Maslow, Joel

Get full text

Safety and Immunogenicity of an Anti–Zika Virus DNA Vaccine by Tebas, Pablo, Roberts, Christine C, Muthumani, Kar, Reuschel, Emma L, Kudchodkar, Sagar B, Zaidi, Faraz I, White, Scott, Khan, Amir S, Racine, Trina, Choi, Hyeree, Boyer, Jean, Park, Young K, Trottier, Sylvie, Remigio, Celine, Krieger, Diane, Spruill, Susan E, Bagarazzi, Mark, Kobinger, Gary P, Weiner, David B, Maslow, Joel N

“…There are no known specific therapies or vaccines to treat or prevent Zika virus infection. In this report, encouraging data are presented from a phase 1 study…”
Get full text

The cost and challenge of vaccine development for emerging and emergent infectious diseases by Maslow, Joel N

Get full text

Vaccines for emerging infectious diseases: Lessons from MERS coronavirus and Zika virus by Maslow, Joel N.

“…The past decade and a half has been characterized by numerous emerging infectious diseases. With each new threat, there has been a call for rapid vaccine…”
Get full text

Challenges and solutions in the development of vaccines against emerging and neglected infectious diseases by Maslow, Joel N.

“…Emerging and emergent infectious diseases (EIDs) represent a significant and growing cause of morbidity and mortality with increased potential for pandemics…”
Get full text

Efficient electrospray deposition of surfaces smaller than the spray plume by Park, Sarah H., Lei, Lin, D’Souza, Darrel, Zipkin, Robert, DiMartini, Emily T., Atzampou, Maria, Lallow, Emran O., Shan, Jerry W., Zahn, Jeffrey D., Shreiber, David I., Lin, Hao, Maslow, Joel N., Singer, Jonathan P.

“…Electrospray deposition (ESD) is a promising technique for depositing micro-/nano-scale droplets and particles with high quality and repeatability. It is…”
Get full text

Zika vaccine development - current progress and challenges for the future by Maslow, Joel N

“…Zika virus is an emergent pathogen that gained significant importance during the epidemic in South and Central America as unusual and alarming complications of…”
Get full text

Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers by Tebas, Pablo, Kraynyak, Kimberly A, Patel, Ami, Maslow, Joel N, Morrow, Matthew P, Sylvester, Albert J, Knoblock, Dawson, Gillespie, Elisabeth, Amante, Dinah, Racine, Trina, McMullan, Trevor, Jeong, Moonsup, Roberts, Christine C, Park, Young K, Boyer, Jean, Broderick, Kate E, Kobinger, Gary P, Bagarazzi, Mark, Weiner, David B, Sardesai, Niranjan Y, White, Scott M

“…Nonlive vaccine approaches that are simple to deliver and stable at room temperature or 2-8°C could be advantageous in controlling future Ebola virus (EBOV)…”
Get full text

Development of a SFTSV DNA vaccine that confers complete protection against lethal infection in ferrets by Kwak, Jeong-Eun, Kim, Young-Il, Park, Su-Jin, Yu, Min-Ah, Kwon, Hyeok-Il, Eo, Sukyeong, Kim, Tae-Shin, Seok, Joon, Choi, Won-Suk, Jeong, Ju Hwan, Lee, Hyojin, Cho, Youngran, Kwon, Jin Ah, Jeong, Moonsup, Maslow, Joel N., Kim, Yong-Eun, Jeon, Haili, Kim, Kee K., Shin, Eui-Cheol, Song, Min-Suk, Jung, Jae U., Choi, Young Ki, Park, Su-Hyung

“…Although the incidence of severe fever with thrombocytopenia syndrome virus (SFTSV) infection has increased from its discovery with a mortality rate of 10–20%,…”
Get full text

Zika Virus: A Brief History and Review of Its Pathogenesis Rediscovered by Maslow, Joel N, Roberts, Christine C

“…From its discovery in Uganda in 1947, Zika virus (ZIKV) was considered a relatively innocuous viral pathogen with sporadic and infrequent occurrence of human…”
Get more information

IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T cell frequency and increases virus-specific T cell responses by Han, Ji Won, Sung, Pil Soo, Hong, Seon-Hui, Lee, Hoyoung, Koh, June Young, Lee, Hyojin, White, Scott, Maslow, Joel N., Weiner, David B., Park, Su-Hyung, Jeong, Moonsup, Heo, Jeong, Ahn, Sang Hoon, Shin, Eui-Cheol

“…Although direct-acting antiviral (DAA) treatment results in a sustained virologic response (SVR) in most patients with chronic HCV infection, they are at risk…”
Get full text

Tuberculosis at the human–animal interface: An emerging disease of elephants by Mikota, Susan K, Maslow, Joel N

“…Summary Over the past 15 years, cases of infection with organisms of the Mycobacterium tuberculosis complex have been diagnosed among captive elephants in the…”
Get full text

Preclinical safety assessment of the suction-assisted intradermal injection of the SARS-CoV-2 DNA vaccine candidate pGO-1002 in white rabbit by Oh, Seunghee, Jang, Min Seong, Jung, Kyung Jin, Han, Ji-Seok, Lee, Hyojin, Gil, Areum, Jeon, Bohyun, Roberts, Christine C., Maslow, Joel N., Kim, Yong-Bum, Han, Kang-Hyun

“…pGO-1002, a non-viral DNA vaccine that expresses both spike and ORF3a antigens of SARS-CoV-2, is undergoing phase 1 and phase 2a clinical trials in Korea and…”
Get full text

Safety and immunogenicity of the bi-cistronic GLS-5310 COVID-19 DNA vaccine delivered with the GeneDerm suction device by Kim, Woo Joo, Roberts, Christine C., Song, Joon Young, Yoon, Jin Gu, Seong, Hye, Hyun, Hak-Jun, Lee, Hyojin, Gil, Areum, Oh, Yeeun, Park, Ji-eun, Jeon, Bohyun, Lee, Ji-Eun, Choi, Sang Kyu, Yoon, Sun Kyung, Lee, Sunhee, Kim, Byoungguk, Kane, Deborah, Spruill, Susan, Kudchodkar, Sagar B., Muthumani, Kar, Park, Young K., Kwon, Ijoo, Jeong, Moonsup, Maslow, Joel N.

“…•This study reports the safety and immunogenicity of the GLS-5310 DNA vaccine through 48 weeks.•First clinical application of the GeneDerm suction device for…”
Get full text

Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2 followed by administration of an mRNA vaccine heterologous boost by Kim, Woo Joo, Roberts, Christine C., Song, Joon Young, Yoon, Jin Gu, Seong, Hye, Hyun, Hak-Jun, Lee, Hyojin, Gil, Areum, Oh, Yeeun, Park, Ji-Eun, Lee, Ji-Eun, Jeon, Bohyun, Kane, Deborah, Spruill, Susan, Kudchodkar, Sagar B., Muthumani, Kar, Park, Young K., Kwon, Ijoo, Maslow, Joel N.

“…•Heterologous mRNA boost following GLS-5310 DNA vaccination was well tolerated.•Neutralizing antibody responses were enhanced 110 fold to GMT of…”
Get full text

Rapid response to an emerging infectious disease – Lessons learned from development of a synthetic DNA vaccine targeting Zika virus by Kudchodkar, Sagar B., Choi, Hyeree, Reuschel, Emma L., Esquivel, Rianne, Jin-Ah Kwon, Jackie, Jeong, Moonsup, Maslow, Joel N., Reed, Charles C., White, Scott, Kim, J. Joseph, Kobinger, Gary P., Tebas, Pablo, Weiner, David B., Muthumani, Kar

“…Vaccines are considered one of the greatest advances in modern medicine. The global burden of numerous infectious diseases has been significantly reduced, and…”
Get full text

Global distribution and epidemiologic associations of Escherichia coli clonal group A, 1998-2007 by Johnson, James R, Menard, Megan E, Lauderdale, Tsai-Ling, Kosmidis, Chris, Gordon, David, Collignon, Peter, Maslow, Joel N, Andrasević, Arjana Tambić, Kuskowski, Michael A

“…Escherichia coli clonal group A (CGA) was first reported in 2001 as an emerging multidrug-resistant extraintestinal pathogen. Because CGA has considerable…”
Get full text

The International Threat of Antimicrobial Resistance: The Perils of Paradise by Maslow, Joel N.

Get full text

DNA Vaccines for Epidemic Preparedness: SARS-CoV-2 and Beyond by Maslow, Joel N, Kwon, Ijoo, Kudchodkar, Sagar B, Kane, Deborah, Tadesse, Amha, Lee, Hyojin, Park, Young K, Muthumani, Kar, Roberts, Christine C

“…We highlight the significant progress in developing DNA vaccines during the SARS-CoV-2 pandemic. Specifically, we provide a comprehensive review of the DNA…”
Get full text